Commitments	3 Months Ended
Mar. 31, 2016
Commitments.
Commitments	9. Commitments In June 2015, we entered into a contract with a third party for up to $3.8 million in clinical manufacturing supplies to support our ongoing clinical trials for ganaxolone. Partial delivery occurred in the first quarter of 2016, and future deliveries are expected later in 2016. We recorded $1.3 million of research and development expense in the first quarter of 2016 related to these supplies, of which $0.3 million is included in accrued expenses as of March 31, 2016. The balance of $2.8 million is due in 2016..

Commitments

3 Months Ended

Mar. 31, 2016

9. Commitments

In June 2015, we entered into a contract with a third party for up to $3.8 million in clinical manufacturing supplies to support our ongoing clinical trials for ganaxolone. Partial delivery occurred in the first quarter of 2016, and future deliveries are expected later in 2016. We recorded $1.3 million of research and development expense in the first quarter of 2016 related to these supplies, of which $0.3 million is included in accrued expenses as of March 31, 2016. The balance of $2.8 million is due in 2016..